Global Amphetamine Drug Market

Amphetamine Drug Comprehensive Study by Type (Generic, Branded), End Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Route of Administration (Oral, Parenteral, Inhalations, Others), Disease (ADHD, Narcolepsy, Obesity, Depression, Others), Sales Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Patient (Adult, Children) Players and Region - Global Market Outlook to 2026

Amphetamine Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Amphetamine Drug Market Scope
Amphetamine is a powerful stimulator of the central nervous system. it is used to treat some medical conditions, but it is also extremely addictive, with a history of abuse. Amphetamine Drug is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine belongs to a category of drugs referred to as stimulants. It can help increase your ability to listen, stay focused on an activity, and control behavior issues. It may also help you to organize your tasks and improve listening skills.

The Amphetamine Drug market study is segmented and major geographies with country level break-up.

There are various companies that are exploring the market opportunities by investing in the new treatment and also expanding their footprints in new geographic regions by adopting various strategic initiatives such as mergers & acquisitions, expansions, investments, new product launches, and others. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Amphetamine Drug market throughout the predicted period.

Pfizer Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Mallinckrodt Company (United Kingdom), Johnson & Johnson Services, Inc. (United States), Hisamitsu Pharmaceutical Co., Inc. (Japan) and Purdue Pharma L.P. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Amphetamine Drug market by Type, Application and Region.

On the basis of geography, the market of Amphetamine Drug has been segmented into South America (Brazil, Argentina, Chile, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Singapore, Indonesia, Thailand, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Spain, Sweden, Belgium, Finland, Denmark, Russia, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Increasing R&D Activities in Healthcare Sector

Market Drivers
  • Increasing Awareness About Mental Health
  • Changing Lifestyle
  • Increasing Number of Depression and ADHD Patients

Opportunities
  • Rising Investments by Major Market Players
  • Increase In Number of Disease Awareness Programs

Restraints
  • Potential Side Effects
  • High Cost of The Product

Challenges
  • Stringent Regulatory Factors on Pharmaceuticals
  • The Covid-19 Impact
  • Growing Demand For Low-Priced Generics


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Raw Material Suppliers and End-Use Industries

Report Objectives / Segmentation Covered

By Type
  • Generic
  • Branded

By End Users
  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

By Route of Administration
  • Oral
  • Parenteral
  • Inhalations
  • Others

By Disease
  • ADHD
  • Narcolepsy
  • Obesity
  • Depression
  • Others

By Sales Channel
  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Patient
  • Adult
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Indonesia
    • Thailand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Sweden
    • Belgium
    • Finland
    • Denmark
    • Russia
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness About Mental Health
      • 3.2.2. Changing Lifestyle
      • 3.2.3. Increasing Number of Depression and ADHD Patients
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors on Pharmaceuticals
      • 3.3.2. The Covid-19 Impact
      • 3.3.3. Growing Demand For Low-Priced Generics
    • 3.4. Market Trends
      • 3.4.1. Increasing R&D Activities in Healthcare Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Amphetamine Drug, by Type, End Users, Route of Administration, Disease, Sales Channel, Patient and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Amphetamine Drug (Value)
      • 5.2.1. Global Amphetamine Drug by: Type (Value)
        • 5.2.1.1. Generic
        • 5.2.1.2. Branded
      • 5.2.2. Global Amphetamine Drug by: Type (Value)
        • 5.2.2.1. Generic
        • 5.2.2.2. Branded
      • 5.2.3. Global Amphetamine Drug by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Home Healthcare
        • 5.2.3.4. Others
      • 5.2.4. Global Amphetamine Drug by: Route of Administration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Parenteral
        • 5.2.4.3. Inhalations
        • 5.2.4.4. Others
      • 5.2.5. Global Amphetamine Drug by: Disease (Value)
        • 5.2.5.1. ADHD
        • 5.2.5.2. Narcolepsy
        • 5.2.5.3. Obesity
        • 5.2.5.4. Depression
        • 5.2.5.5. Others
      • 5.2.6. Global Amphetamine Drug by: Sales Channel (Value)
        • 5.2.6.1. Direct Tender
        • 5.2.6.2. Hospital Pharmacy
        • 5.2.6.3. Retail Pharmacy
        • 5.2.6.4. Online Pharmacy
        • 5.2.6.5. Others
      • 5.2.7. Global Amphetamine Drug by: Patient (Value)
        • 5.2.7.1. Adult
        • 5.2.7.2. Children
      • 5.2.8. Global Amphetamine Drug Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Chile
          • 5.2.8.1.4. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Singapore
          • 5.2.8.2.6. Indonesia
          • 5.2.8.2.7. Thailand
          • 5.2.8.2.8. Australia
          • 5.2.8.2.9. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Spain
          • 5.2.8.3.7. Sweden
          • 5.2.8.3.8. Belgium
          • 5.2.8.3.9. Finland
          • 5.2.8.3.10. Denmark
          • 5.2.8.3.11. Russia
          • 5.2.8.3.12. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Amphetamine Drug (Volume)
      • 5.3.1. Global Amphetamine Drug by: Type (Volume)
        • 5.3.1.1. Generic
        • 5.3.1.2. Branded
      • 5.3.2. Global Amphetamine Drug by: Type (Volume)
        • 5.3.2.1. Generic
        • 5.3.2.2. Branded
      • 5.3.3. Global Amphetamine Drug by: End Users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Specialty Clinics
        • 5.3.3.3. Home Healthcare
        • 5.3.3.4. Others
      • 5.3.4. Global Amphetamine Drug by: Route of Administration (Volume)
        • 5.3.4.1. Oral
        • 5.3.4.2. Parenteral
        • 5.3.4.3. Inhalations
        • 5.3.4.4. Others
      • 5.3.5. Global Amphetamine Drug by: Disease (Volume)
        • 5.3.5.1. ADHD
        • 5.3.5.2. Narcolepsy
        • 5.3.5.3. Obesity
        • 5.3.5.4. Depression
        • 5.3.5.5. Others
      • 5.3.6. Global Amphetamine Drug by: Sales Channel (Volume)
        • 5.3.6.1. Direct Tender
        • 5.3.6.2. Hospital Pharmacy
        • 5.3.6.3. Retail Pharmacy
        • 5.3.6.4. Online Pharmacy
        • 5.3.6.5. Others
      • 5.3.7. Global Amphetamine Drug by: Patient (Volume)
        • 5.3.7.1. Adult
        • 5.3.7.2. Children
      • 5.3.8. Global Amphetamine Drug Region
        • 5.3.8.1. South America
          • 5.3.8.1.1. Brazil
          • 5.3.8.1.2. Argentina
          • 5.3.8.1.3. Chile
          • 5.3.8.1.4. Rest of South America
        • 5.3.8.2. Asia Pacific
          • 5.3.8.2.1. China
          • 5.3.8.2.2. Japan
          • 5.3.8.2.3. India
          • 5.3.8.2.4. South Korea
          • 5.3.8.2.5. Singapore
          • 5.3.8.2.6. Indonesia
          • 5.3.8.2.7. Thailand
          • 5.3.8.2.8. Australia
          • 5.3.8.2.9. Rest of Asia-Pacific
        • 5.3.8.3. Europe
          • 5.3.8.3.1. Germany
          • 5.3.8.3.2. France
          • 5.3.8.3.3. Italy
          • 5.3.8.3.4. United Kingdom
          • 5.3.8.3.5. Netherlands
          • 5.3.8.3.6. Spain
          • 5.3.8.3.7. Sweden
          • 5.3.8.3.8. Belgium
          • 5.3.8.3.9. Finland
          • 5.3.8.3.10. Denmark
          • 5.3.8.3.11. Russia
          • 5.3.8.3.12. Rest of Europe
        • 5.3.8.4. MEA
          • 5.3.8.4.1. Middle East
          • 5.3.8.4.2. Africa
        • 5.3.8.5. North America
          • 5.3.8.5.1. United States
          • 5.3.8.5.2. Canada
          • 5.3.8.5.3. Mexico
    • 5.4. Global Amphetamine Drug (Price)
  • 6. Amphetamine Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mallinckrodt Company (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Services, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Purdue Pharma L.P. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Amphetamine Drug Sale, by Type, End Users, Route of Administration, Disease, Sales Channel, Patient and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Amphetamine Drug (Value)
      • 7.2.1. Global Amphetamine Drug by: Type (Value)
        • 7.2.1.1. Generic
        • 7.2.1.2. Branded
      • 7.2.2. Global Amphetamine Drug by: Type (Value)
        • 7.2.2.1. Generic
        • 7.2.2.2. Branded
      • 7.2.3. Global Amphetamine Drug by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Home Healthcare
        • 7.2.3.4. Others
      • 7.2.4. Global Amphetamine Drug by: Route of Administration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Parenteral
        • 7.2.4.3. Inhalations
        • 7.2.4.4. Others
      • 7.2.5. Global Amphetamine Drug by: Disease (Value)
        • 7.2.5.1. ADHD
        • 7.2.5.2. Narcolepsy
        • 7.2.5.3. Obesity
        • 7.2.5.4. Depression
        • 7.2.5.5. Others
      • 7.2.6. Global Amphetamine Drug by: Sales Channel (Value)
        • 7.2.6.1. Direct Tender
        • 7.2.6.2. Hospital Pharmacy
        • 7.2.6.3. Retail Pharmacy
        • 7.2.6.4. Online Pharmacy
        • 7.2.6.5. Others
      • 7.2.7. Global Amphetamine Drug by: Patient (Value)
        • 7.2.7.1. Adult
        • 7.2.7.2. Children
      • 7.2.8. Global Amphetamine Drug Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Chile
          • 7.2.8.1.4. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Singapore
          • 7.2.8.2.6. Indonesia
          • 7.2.8.2.7. Thailand
          • 7.2.8.2.8. Australia
          • 7.2.8.2.9. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Spain
          • 7.2.8.3.7. Sweden
          • 7.2.8.3.8. Belgium
          • 7.2.8.3.9. Finland
          • 7.2.8.3.10. Denmark
          • 7.2.8.3.11. Russia
          • 7.2.8.3.12. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Amphetamine Drug (Volume)
      • 7.3.1. Global Amphetamine Drug by: Type (Volume)
        • 7.3.1.1. Generic
        • 7.3.1.2. Branded
      • 7.3.2. Global Amphetamine Drug by: Type (Volume)
        • 7.3.2.1. Generic
        • 7.3.2.2. Branded
      • 7.3.3. Global Amphetamine Drug by: End Users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Specialty Clinics
        • 7.3.3.3. Home Healthcare
        • 7.3.3.4. Others
      • 7.3.4. Global Amphetamine Drug by: Route of Administration (Volume)
        • 7.3.4.1. Oral
        • 7.3.4.2. Parenteral
        • 7.3.4.3. Inhalations
        • 7.3.4.4. Others
      • 7.3.5. Global Amphetamine Drug by: Disease (Volume)
        • 7.3.5.1. ADHD
        • 7.3.5.2. Narcolepsy
        • 7.3.5.3. Obesity
        • 7.3.5.4. Depression
        • 7.3.5.5. Others
      • 7.3.6. Global Amphetamine Drug by: Sales Channel (Volume)
        • 7.3.6.1. Direct Tender
        • 7.3.6.2. Hospital Pharmacy
        • 7.3.6.3. Retail Pharmacy
        • 7.3.6.4. Online Pharmacy
        • 7.3.6.5. Others
      • 7.3.7. Global Amphetamine Drug by: Patient (Volume)
        • 7.3.7.1. Adult
        • 7.3.7.2. Children
      • 7.3.8. Global Amphetamine Drug Region
        • 7.3.8.1. South America
          • 7.3.8.1.1. Brazil
          • 7.3.8.1.2. Argentina
          • 7.3.8.1.3. Chile
          • 7.3.8.1.4. Rest of South America
        • 7.3.8.2. Asia Pacific
          • 7.3.8.2.1. China
          • 7.3.8.2.2. Japan
          • 7.3.8.2.3. India
          • 7.3.8.2.4. South Korea
          • 7.3.8.2.5. Singapore
          • 7.3.8.2.6. Indonesia
          • 7.3.8.2.7. Thailand
          • 7.3.8.2.8. Australia
          • 7.3.8.2.9. Rest of Asia-Pacific
        • 7.3.8.3. Europe
          • 7.3.8.3.1. Germany
          • 7.3.8.3.2. France
          • 7.3.8.3.3. Italy
          • 7.3.8.3.4. United Kingdom
          • 7.3.8.3.5. Netherlands
          • 7.3.8.3.6. Spain
          • 7.3.8.3.7. Sweden
          • 7.3.8.3.8. Belgium
          • 7.3.8.3.9. Finland
          • 7.3.8.3.10. Denmark
          • 7.3.8.3.11. Russia
          • 7.3.8.3.12. Rest of Europe
        • 7.3.8.4. MEA
          • 7.3.8.4.1. Middle East
          • 7.3.8.4.2. Africa
        • 7.3.8.5. North America
          • 7.3.8.5.1. United States
          • 7.3.8.5.2. Canada
          • 7.3.8.5.3. Mexico
    • 7.4. Global Amphetamine Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Amphetamine Drug: by Type(USD Million)
  • Table 2. Amphetamine Drug Generic , by Region USD Million (2015-2020)
  • Table 3. Amphetamine Drug Branded , by Region USD Million (2015-2020)
  • Table 4. Amphetamine Drug: by Type(USD Million)
  • Table 5. Amphetamine Drug Generic , by Region USD Million (2015-2020)
  • Table 6. Amphetamine Drug Branded , by Region USD Million (2015-2020)
  • Table 7. Amphetamine Drug: by End Users(USD Million)
  • Table 8. Amphetamine Drug Hospitals , by Region USD Million (2015-2020)
  • Table 9. Amphetamine Drug Specialty Clinics , by Region USD Million (2015-2020)
  • Table 10. Amphetamine Drug Home Healthcare , by Region USD Million (2015-2020)
  • Table 11. Amphetamine Drug Others , by Region USD Million (2015-2020)
  • Table 12. Amphetamine Drug: by Route of Administration(USD Million)
  • Table 13. Amphetamine Drug Oral , by Region USD Million (2015-2020)
  • Table 14. Amphetamine Drug Parenteral , by Region USD Million (2015-2020)
  • Table 15. Amphetamine Drug Inhalations , by Region USD Million (2015-2020)
  • Table 16. Amphetamine Drug Others , by Region USD Million (2015-2020)
  • Table 17. Amphetamine Drug: by Disease(USD Million)
  • Table 18. Amphetamine Drug ADHD , by Region USD Million (2015-2020)
  • Table 19. Amphetamine Drug Narcolepsy , by Region USD Million (2015-2020)
  • Table 20. Amphetamine Drug Obesity , by Region USD Million (2015-2020)
  • Table 21. Amphetamine Drug Depression , by Region USD Million (2015-2020)
  • Table 22. Amphetamine Drug Others , by Region USD Million (2015-2020)
  • Table 23. Amphetamine Drug: by Sales Channel(USD Million)
  • Table 24. Amphetamine Drug Direct Tender , by Region USD Million (2015-2020)
  • Table 25. Amphetamine Drug Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 26. Amphetamine Drug Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 27. Amphetamine Drug Online Pharmacy , by Region USD Million (2015-2020)
  • Table 28. Amphetamine Drug Others , by Region USD Million (2015-2020)
  • Table 29. Amphetamine Drug: by Patient(USD Million)
  • Table 30. Amphetamine Drug Adult , by Region USD Million (2015-2020)
  • Table 31. Amphetamine Drug Children , by Region USD Million (2015-2020)
  • Table 32. South America Amphetamine Drug, by Country USD Million (2015-2020)
  • Table 33. South America Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 34. South America Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 35. South America Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 36. South America Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 37. South America Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 38. South America Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 39. Brazil Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 40. Brazil Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 41. Brazil Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 42. Brazil Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 43. Brazil Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 44. Brazil Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 45. Argentina Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 46. Argentina Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 47. Argentina Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 48. Argentina Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 49. Argentina Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 50. Argentina Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 51. Chile Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 52. Chile Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 53. Chile Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 54. Chile Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 55. Chile Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 56. Chile Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 57. Rest of South America Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 58. Rest of South America Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 59. Rest of South America Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 60. Rest of South America Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 61. Rest of South America Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 62. Rest of South America Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 63. Asia Pacific Amphetamine Drug, by Country USD Million (2015-2020)
  • Table 64. Asia Pacific Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 65. Asia Pacific Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 66. Asia Pacific Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 67. Asia Pacific Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 68. Asia Pacific Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 69. Asia Pacific Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 70. China Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 71. China Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 72. China Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 73. China Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 74. China Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 75. China Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 76. Japan Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 77. Japan Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 78. Japan Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 79. Japan Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 80. Japan Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 81. Japan Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 82. India Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 83. India Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 84. India Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 85. India Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 86. India Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 87. India Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 88. South Korea Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 89. South Korea Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 90. South Korea Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 91. South Korea Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 92. South Korea Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 93. South Korea Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 94. Singapore Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 95. Singapore Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 96. Singapore Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 97. Singapore Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 98. Singapore Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 99. Singapore Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 100. Indonesia Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 101. Indonesia Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 102. Indonesia Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 103. Indonesia Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 104. Indonesia Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 105. Indonesia Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 106. Thailand Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 107. Thailand Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 108. Thailand Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 109. Thailand Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 110. Thailand Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 111. Thailand Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 112. Australia Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 113. Australia Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 114. Australia Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 115. Australia Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 116. Australia Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 117. Australia Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 118. Rest of Asia-Pacific Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 119. Rest of Asia-Pacific Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 120. Rest of Asia-Pacific Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 121. Rest of Asia-Pacific Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 122. Rest of Asia-Pacific Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 123. Rest of Asia-Pacific Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 124. Europe Amphetamine Drug, by Country USD Million (2015-2020)
  • Table 125. Europe Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 126. Europe Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 127. Europe Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 128. Europe Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 129. Europe Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 130. Europe Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 131. Germany Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 132. Germany Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 133. Germany Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 134. Germany Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 135. Germany Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 136. Germany Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 137. France Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 138. France Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 139. France Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 140. France Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 141. France Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 142. France Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 143. Italy Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 144. Italy Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 145. Italy Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 146. Italy Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 147. Italy Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 148. Italy Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 149. United Kingdom Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 150. United Kingdom Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 151. United Kingdom Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 152. United Kingdom Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 153. United Kingdom Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 154. United Kingdom Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 155. Netherlands Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 156. Netherlands Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 157. Netherlands Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 158. Netherlands Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 159. Netherlands Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 160. Netherlands Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 161. Spain Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 162. Spain Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 163. Spain Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 164. Spain Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 165. Spain Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 166. Spain Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 167. Sweden Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 168. Sweden Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 169. Sweden Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 170. Sweden Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 171. Sweden Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 172. Sweden Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 173. Belgium Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 174. Belgium Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 175. Belgium Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 176. Belgium Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 177. Belgium Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 178. Belgium Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 179. Finland Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 180. Finland Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 181. Finland Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 182. Finland Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 183. Finland Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 184. Finland Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 185. Denmark Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 186. Denmark Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 187. Denmark Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 188. Denmark Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 189. Denmark Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 190. Denmark Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 191. Russia Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 192. Russia Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 193. Russia Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 194. Russia Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 195. Russia Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 196. Russia Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 197. Rest of Europe Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 198. Rest of Europe Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 199. Rest of Europe Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 200. Rest of Europe Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 201. Rest of Europe Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 202. Rest of Europe Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 203. MEA Amphetamine Drug, by Country USD Million (2015-2020)
  • Table 204. MEA Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 205. MEA Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 206. MEA Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 207. MEA Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 208. MEA Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 209. MEA Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 210. Middle East Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 211. Middle East Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 212. Middle East Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 213. Middle East Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 214. Middle East Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 215. Middle East Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 216. Africa Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 217. Africa Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 218. Africa Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 219. Africa Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 220. Africa Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 221. Africa Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 222. North America Amphetamine Drug, by Country USD Million (2015-2020)
  • Table 223. North America Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 224. North America Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 225. North America Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 226. North America Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 227. North America Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 228. North America Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 229. United States Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 230. United States Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 231. United States Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 232. United States Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 233. United States Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 234. United States Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 235. Canada Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 236. Canada Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 237. Canada Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 238. Canada Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 239. Canada Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 240. Canada Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 241. Mexico Amphetamine Drug, by Type USD Million (2015-2020)
  • Table 242. Mexico Amphetamine Drug, by End Users USD Million (2015-2020)
  • Table 243. Mexico Amphetamine Drug, by Route of Administration USD Million (2015-2020)
  • Table 244. Mexico Amphetamine Drug, by Disease USD Million (2015-2020)
  • Table 245. Mexico Amphetamine Drug, by Sales Channel USD Million (2015-2020)
  • Table 246. Mexico Amphetamine Drug, by Patient USD Million (2015-2020)
  • Table 247. Amphetamine Drug Sales: by Type(K Tons)
  • Table 248. Amphetamine Drug Sales Generic , by Region K Tons (2015-2020)
  • Table 249. Amphetamine Drug Sales Branded , by Region K Tons (2015-2020)
  • Table 250. Amphetamine Drug Sales: by Type(K Tons)
  • Table 251. Amphetamine Drug Sales Generic , by Region K Tons (2015-2020)
  • Table 252. Amphetamine Drug Sales Branded , by Region K Tons (2015-2020)
  • Table 253. Amphetamine Drug Sales: by End Users(K Tons)
  • Table 254. Amphetamine Drug Sales Hospitals , by Region K Tons (2015-2020)
  • Table 255. Amphetamine Drug Sales Specialty Clinics , by Region K Tons (2015-2020)
  • Table 256. Amphetamine Drug Sales Home Healthcare , by Region K Tons (2015-2020)
  • Table 257. Amphetamine Drug Sales Others , by Region K Tons (2015-2020)
  • Table 258. Amphetamine Drug Sales: by Route of Administration(K Tons)
  • Table 259. Amphetamine Drug Sales Oral , by Region K Tons (2015-2020)
  • Table 260. Amphetamine Drug Sales Parenteral , by Region K Tons (2015-2020)
  • Table 261. Amphetamine Drug Sales Inhalations , by Region K Tons (2015-2020)
  • Table 262. Amphetamine Drug Sales Others , by Region K Tons (2015-2020)
  • Table 263. Amphetamine Drug Sales: by Disease(K Tons)
  • Table 264. Amphetamine Drug Sales ADHD , by Region K Tons (2015-2020)
  • Table 265. Amphetamine Drug Sales Narcolepsy , by Region K Tons (2015-2020)
  • Table 266. Amphetamine Drug Sales Obesity , by Region K Tons (2015-2020)
  • Table 267. Amphetamine Drug Sales Depression , by Region K Tons (2015-2020)
  • Table 268. Amphetamine Drug Sales Others , by Region K Tons (2015-2020)
  • Table 269. Amphetamine Drug Sales: by Sales Channel(K Tons)
  • Table 270. Amphetamine Drug Sales Direct Tender , by Region K Tons (2015-2020)
  • Table 271. Amphetamine Drug Sales Hospital Pharmacy , by Region K Tons (2015-2020)
  • Table 272. Amphetamine Drug Sales Retail Pharmacy , by Region K Tons (2015-2020)
  • Table 273. Amphetamine Drug Sales Online Pharmacy , by Region K Tons (2015-2020)
  • Table 274. Amphetamine Drug Sales Others , by Region K Tons (2015-2020)
  • Table 275. Amphetamine Drug Sales: by Patient(K Tons)
  • Table 276. Amphetamine Drug Sales Adult , by Region K Tons (2015-2020)
  • Table 277. Amphetamine Drug Sales Children , by Region K Tons (2015-2020)
  • Table 278. South America Amphetamine Drug Sales, by Country K Tons (2015-2020)
  • Table 279. South America Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 280. South America Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 281. South America Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 282. South America Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 283. South America Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 284. South America Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 285. Brazil Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 286. Brazil Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 287. Brazil Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 288. Brazil Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 289. Brazil Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 290. Brazil Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 291. Argentina Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 292. Argentina Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 293. Argentina Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 294. Argentina Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 295. Argentina Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 296. Argentina Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 297. Chile Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 298. Chile Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 299. Chile Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 300. Chile Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 301. Chile Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 302. Chile Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 303. Rest of South America Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 304. Rest of South America Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 305. Rest of South America Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 306. Rest of South America Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 307. Rest of South America Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 308. Rest of South America Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 309. Asia Pacific Amphetamine Drug Sales, by Country K Tons (2015-2020)
  • Table 310. Asia Pacific Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 311. Asia Pacific Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 312. Asia Pacific Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 313. Asia Pacific Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 314. Asia Pacific Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 315. Asia Pacific Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 316. China Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 317. China Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 318. China Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 319. China Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 320. China Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 321. China Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 322. Japan Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 323. Japan Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 324. Japan Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 325. Japan Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 326. Japan Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 327. Japan Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 328. India Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 329. India Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 330. India Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 331. India Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 332. India Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 333. India Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 334. South Korea Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 335. South Korea Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 336. South Korea Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 337. South Korea Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 338. South Korea Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 339. South Korea Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 340. Singapore Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 341. Singapore Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 342. Singapore Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 343. Singapore Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 344. Singapore Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 345. Singapore Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 346. Indonesia Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 347. Indonesia Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 348. Indonesia Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 349. Indonesia Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 350. Indonesia Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 351. Indonesia Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 352. Thailand Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 353. Thailand Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 354. Thailand Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 355. Thailand Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 356. Thailand Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 357. Thailand Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 358. Australia Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 359. Australia Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 360. Australia Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 361. Australia Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 362. Australia Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 363. Australia Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 364. Rest of Asia-Pacific Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 365. Rest of Asia-Pacific Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 366. Rest of Asia-Pacific Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 367. Rest of Asia-Pacific Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 368. Rest of Asia-Pacific Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 369. Rest of Asia-Pacific Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 370. Europe Amphetamine Drug Sales, by Country K Tons (2015-2020)
  • Table 371. Europe Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 372. Europe Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 373. Europe Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 374. Europe Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 375. Europe Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 376. Europe Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 377. Germany Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 378. Germany Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 379. Germany Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 380. Germany Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 381. Germany Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 382. Germany Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 383. France Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 384. France Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 385. France Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 386. France Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 387. France Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 388. France Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 389. Italy Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 390. Italy Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 391. Italy Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 392. Italy Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 393. Italy Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 394. Italy Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 395. United Kingdom Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 396. United Kingdom Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 397. United Kingdom Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 398. United Kingdom Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 399. United Kingdom Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 400. United Kingdom Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 401. Netherlands Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 402. Netherlands Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 403. Netherlands Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 404. Netherlands Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 405. Netherlands Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 406. Netherlands Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 407. Spain Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 408. Spain Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 409. Spain Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 410. Spain Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 411. Spain Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 412. Spain Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 413. Sweden Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 414. Sweden Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 415. Sweden Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 416. Sweden Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 417. Sweden Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 418. Sweden Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 419. Belgium Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 420. Belgium Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 421. Belgium Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 422. Belgium Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 423. Belgium Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 424. Belgium Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 425. Finland Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 426. Finland Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 427. Finland Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 428. Finland Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 429. Finland Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 430. Finland Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 431. Denmark Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 432. Denmark Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 433. Denmark Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 434. Denmark Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 435. Denmark Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 436. Denmark Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 437. Russia Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 438. Russia Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 439. Russia Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 440. Russia Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 441. Russia Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 442. Russia Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 443. Rest of Europe Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 444. Rest of Europe Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 445. Rest of Europe Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 446. Rest of Europe Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 447. Rest of Europe Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 448. Rest of Europe Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 449. MEA Amphetamine Drug Sales, by Country K Tons (2015-2020)
  • Table 450. MEA Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 451. MEA Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 452. MEA Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 453. MEA Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 454. MEA Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 455. MEA Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 456. Middle East Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 457. Middle East Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 458. Middle East Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 459. Middle East Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 460. Middle East Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 461. Middle East Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 462. Africa Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 463. Africa Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 464. Africa Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 465. Africa Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 466. Africa Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 467. Africa Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 468. North America Amphetamine Drug Sales, by Country K Tons (2015-2020)
  • Table 469. North America Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 470. North America Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 471. North America Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 472. North America Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 473. North America Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 474. North America Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 475. United States Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 476. United States Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 477. United States Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 478. United States Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 479. United States Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 480. United States Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 481. Canada Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 482. Canada Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 483. Canada Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 484. Canada Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 485. Canada Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 486. Canada Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 487. Mexico Amphetamine Drug Sales, by Type K Tons (2015-2020)
  • Table 488. Mexico Amphetamine Drug Sales, by End Users K Tons (2015-2020)
  • Table 489. Mexico Amphetamine Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 490. Mexico Amphetamine Drug Sales, by Disease K Tons (2015-2020)
  • Table 491. Mexico Amphetamine Drug Sales, by Sales Channel K Tons (2015-2020)
  • Table 492. Mexico Amphetamine Drug Sales, by Patient K Tons (2015-2020)
  • Table 493. Company Basic Information, Sales Area and Its Competitors
  • Table 494. Company Basic Information, Sales Area and Its Competitors
  • Table 495. Company Basic Information, Sales Area and Its Competitors
  • Table 496. Company Basic Information, Sales Area and Its Competitors
  • Table 497. Company Basic Information, Sales Area and Its Competitors
  • Table 498. Company Basic Information, Sales Area and Its Competitors
  • Table 499. Company Basic Information, Sales Area and Its Competitors
  • Table 500. Company Basic Information, Sales Area and Its Competitors
  • Table 501. Amphetamine Drug: by Type(USD Million)
  • Table 502. Amphetamine Drug Generic , by Region USD Million (2021-2026)
  • Table 503. Amphetamine Drug Branded , by Region USD Million (2021-2026)
  • Table 504. Amphetamine Drug: by Type(USD Million)
  • Table 505. Amphetamine Drug Generic , by Region USD Million (2021-2026)
  • Table 506. Amphetamine Drug Branded , by Region USD Million (2021-2026)
  • Table 507. Amphetamine Drug: by End Users(USD Million)
  • Table 508. Amphetamine Drug Hospitals , by Region USD Million (2021-2026)
  • Table 509. Amphetamine Drug Specialty Clinics , by Region USD Million (2021-2026)
  • Table 510. Amphetamine Drug Home Healthcare , by Region USD Million (2021-2026)
  • Table 511. Amphetamine Drug Others , by Region USD Million (2021-2026)
  • Table 512. Amphetamine Drug: by Route of Administration(USD Million)
  • Table 513. Amphetamine Drug Oral , by Region USD Million (2021-2026)
  • Table 514. Amphetamine Drug Parenteral , by Region USD Million (2021-2026)
  • Table 515. Amphetamine Drug Inhalations , by Region USD Million (2021-2026)
  • Table 516. Amphetamine Drug Others , by Region USD Million (2021-2026)
  • Table 517. Amphetamine Drug: by Disease(USD Million)
  • Table 518. Amphetamine Drug ADHD , by Region USD Million (2021-2026)
  • Table 519. Amphetamine Drug Narcolepsy , by Region USD Million (2021-2026)
  • Table 520. Amphetamine Drug Obesity , by Region USD Million (2021-2026)
  • Table 521. Amphetamine Drug Depression , by Region USD Million (2021-2026)
  • Table 522. Amphetamine Drug Others , by Region USD Million (2021-2026)
  • Table 523. Amphetamine Drug: by Sales Channel(USD Million)
  • Table 524. Amphetamine Drug Direct Tender , by Region USD Million (2021-2026)
  • Table 525. Amphetamine Drug Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 526. Amphetamine Drug Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 527. Amphetamine Drug Online Pharmacy , by Region USD Million (2021-2026)
  • Table 528. Amphetamine Drug Others , by Region USD Million (2021-2026)
  • Table 529. Amphetamine Drug: by Patient(USD Million)
  • Table 530. Amphetamine Drug Adult , by Region USD Million (2021-2026)
  • Table 531. Amphetamine Drug Children , by Region USD Million (2021-2026)
  • Table 532. South America Amphetamine Drug, by Country USD Million (2021-2026)
  • Table 533. South America Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 534. South America Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 535. South America Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 536. South America Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 537. South America Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 538. South America Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 539. Brazil Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 540. Brazil Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 541. Brazil Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 542. Brazil Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 543. Brazil Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 544. Brazil Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 545. Argentina Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 546. Argentina Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 547. Argentina Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 548. Argentina Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 549. Argentina Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 550. Argentina Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 551. Chile Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 552. Chile Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 553. Chile Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 554. Chile Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 555. Chile Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 556. Chile Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 557. Rest of South America Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 558. Rest of South America Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 559. Rest of South America Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 560. Rest of South America Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 561. Rest of South America Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 562. Rest of South America Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 563. Asia Pacific Amphetamine Drug, by Country USD Million (2021-2026)
  • Table 564. Asia Pacific Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 565. Asia Pacific Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 566. Asia Pacific Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 567. Asia Pacific Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 568. Asia Pacific Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 569. Asia Pacific Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 570. China Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 571. China Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 572. China Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 573. China Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 574. China Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 575. China Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 576. Japan Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 577. Japan Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 578. Japan Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 579. Japan Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 580. Japan Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 581. Japan Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 582. India Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 583. India Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 584. India Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 585. India Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 586. India Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 587. India Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 588. South Korea Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 589. South Korea Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 590. South Korea Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 591. South Korea Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 592. South Korea Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 593. South Korea Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 594. Singapore Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 595. Singapore Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 596. Singapore Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 597. Singapore Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 598. Singapore Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 599. Singapore Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 600. Indonesia Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 601. Indonesia Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 602. Indonesia Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 603. Indonesia Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 604. Indonesia Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 605. Indonesia Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 606. Thailand Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 607. Thailand Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 608. Thailand Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 609. Thailand Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 610. Thailand Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 611. Thailand Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 612. Australia Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 613. Australia Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 614. Australia Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 615. Australia Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 616. Australia Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 617. Australia Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 618. Rest of Asia-Pacific Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 619. Rest of Asia-Pacific Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 620. Rest of Asia-Pacific Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 621. Rest of Asia-Pacific Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 622. Rest of Asia-Pacific Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 623. Rest of Asia-Pacific Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 624. Europe Amphetamine Drug, by Country USD Million (2021-2026)
  • Table 625. Europe Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 626. Europe Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 627. Europe Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 628. Europe Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 629. Europe Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 630. Europe Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 631. Germany Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 632. Germany Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 633. Germany Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 634. Germany Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 635. Germany Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 636. Germany Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 637. France Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 638. France Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 639. France Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 640. France Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 641. France Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 642. France Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 643. Italy Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 644. Italy Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 645. Italy Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 646. Italy Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 647. Italy Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 648. Italy Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 649. United Kingdom Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 650. United Kingdom Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 651. United Kingdom Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 652. United Kingdom Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 653. United Kingdom Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 654. United Kingdom Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 655. Netherlands Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 656. Netherlands Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 657. Netherlands Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 658. Netherlands Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 659. Netherlands Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 660. Netherlands Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 661. Spain Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 662. Spain Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 663. Spain Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 664. Spain Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 665. Spain Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 666. Spain Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 667. Sweden Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 668. Sweden Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 669. Sweden Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 670. Sweden Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 671. Sweden Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 672. Sweden Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 673. Belgium Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 674. Belgium Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 675. Belgium Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 676. Belgium Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 677. Belgium Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 678. Belgium Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 679. Finland Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 680. Finland Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 681. Finland Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 682. Finland Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 683. Finland Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 684. Finland Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 685. Denmark Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 686. Denmark Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 687. Denmark Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 688. Denmark Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 689. Denmark Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 690. Denmark Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 691. Russia Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 692. Russia Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 693. Russia Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 694. Russia Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 695. Russia Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 696. Russia Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 697. Rest of Europe Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 698. Rest of Europe Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 699. Rest of Europe Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 700. Rest of Europe Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 701. Rest of Europe Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 702. Rest of Europe Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 703. MEA Amphetamine Drug, by Country USD Million (2021-2026)
  • Table 704. MEA Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 705. MEA Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 706. MEA Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 707. MEA Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 708. MEA Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 709. MEA Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 710. Middle East Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 711. Middle East Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 712. Middle East Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 713. Middle East Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 714. Middle East Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 715. Middle East Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 716. Africa Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 717. Africa Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 718. Africa Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 719. Africa Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 720. Africa Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 721. Africa Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 722. North America Amphetamine Drug, by Country USD Million (2021-2026)
  • Table 723. North America Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 724. North America Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 725. North America Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 726. North America Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 727. North America Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 728. North America Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 729. United States Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 730. United States Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 731. United States Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 732. United States Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 733. United States Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 734. United States Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 735. Canada Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 736. Canada Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 737. Canada Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 738. Canada Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 739. Canada Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 740. Canada Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 741. Mexico Amphetamine Drug, by Type USD Million (2021-2026)
  • Table 742. Mexico Amphetamine Drug, by End Users USD Million (2021-2026)
  • Table 743. Mexico Amphetamine Drug, by Route of Administration USD Million (2021-2026)
  • Table 744. Mexico Amphetamine Drug, by Disease USD Million (2021-2026)
  • Table 745. Mexico Amphetamine Drug, by Sales Channel USD Million (2021-2026)
  • Table 746. Mexico Amphetamine Drug, by Patient USD Million (2021-2026)
  • Table 747. Amphetamine Drug Sales: by Type(K Tons)
  • Table 748. Amphetamine Drug Sales Generic , by Region K Tons (2021-2026)
  • Table 749. Amphetamine Drug Sales Branded , by Region K Tons (2021-2026)
  • Table 750. Amphetamine Drug Sales: by Type(K Tons)
  • Table 751. Amphetamine Drug Sales Generic , by Region K Tons (2021-2026)
  • Table 752. Amphetamine Drug Sales Branded , by Region K Tons (2021-2026)
  • Table 753. Amphetamine Drug Sales: by End Users(K Tons)
  • Table 754. Amphetamine Drug Sales Hospitals , by Region K Tons (2021-2026)
  • Table 755. Amphetamine Drug Sales Specialty Clinics , by Region K Tons (2021-2026)
  • Table 756. Amphetamine Drug Sales Home Healthcare , by Region K Tons (2021-2026)
  • Table 757. Amphetamine Drug Sales Others , by Region K Tons (2021-2026)
  • Table 758. Amphetamine Drug Sales: by Route of Administration(K Tons)
  • Table 759. Amphetamine Drug Sales Oral , by Region K Tons (2021-2026)
  • Table 760. Amphetamine Drug Sales Parenteral , by Region K Tons (2021-2026)
  • Table 761. Amphetamine Drug Sales Inhalations , by Region K Tons (2021-2026)
  • Table 762. Amphetamine Drug Sales Others , by Region K Tons (2021-2026)
  • Table 763. Amphetamine Drug Sales: by Disease(K Tons)
  • Table 764. Amphetamine Drug Sales ADHD , by Region K Tons (2021-2026)
  • Table 765. Amphetamine Drug Sales Narcolepsy , by Region K Tons (2021-2026)
  • Table 766. Amphetamine Drug Sales Obesity , by Region K Tons (2021-2026)
  • Table 767. Amphetamine Drug Sales Depression , by Region K Tons (2021-2026)
  • Table 768. Amphetamine Drug Sales Others , by Region K Tons (2021-2026)
  • Table 769. Amphetamine Drug Sales: by Sales Channel(K Tons)
  • Table 770. Amphetamine Drug Sales Direct Tender , by Region K Tons (2021-2026)
  • Table 771. Amphetamine Drug Sales Hospital Pharmacy , by Region K Tons (2021-2026)
  • Table 772. Amphetamine Drug Sales Retail Pharmacy , by Region K Tons (2021-2026)
  • Table 773. Amphetamine Drug Sales Online Pharmacy , by Region K Tons (2021-2026)
  • Table 774. Amphetamine Drug Sales Others , by Region K Tons (2021-2026)
  • Table 775. Amphetamine Drug Sales: by Patient(K Tons)
  • Table 776. Amphetamine Drug Sales Adult , by Region K Tons (2021-2026)
  • Table 777. Amphetamine Drug Sales Children , by Region K Tons (2021-2026)
  • Table 778. South America Amphetamine Drug Sales, by Country K Tons (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Amphetamine Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Amphetamine Drug: by Type USD Million (2015-2020)
  • Figure 6. Global Amphetamine Drug: by End Users USD Million (2015-2020)
  • Figure 7. Global Amphetamine Drug: by Route of Administration USD Million (2015-2020)
  • Figure 8. Global Amphetamine Drug: by Disease USD Million (2015-2020)
  • Figure 9. Global Amphetamine Drug: by Sales Channel USD Million (2015-2020)
  • Figure 10. Global Amphetamine Drug: by Patient USD Million (2015-2020)
  • Figure 11. South America Amphetamine Drug Share (%), by Country
  • Figure 12. Asia Pacific Amphetamine Drug Share (%), by Country
  • Figure 13. Europe Amphetamine Drug Share (%), by Country
  • Figure 14. MEA Amphetamine Drug Share (%), by Country
  • Figure 15. North America Amphetamine Drug Share (%), by Country
  • Figure 16. Global Amphetamine Drug: by Type K Tons (2015-2020)
  • Figure 17. Global Amphetamine Drug: by Type K Tons (2015-2020)
  • Figure 18. Global Amphetamine Drug: by End Users K Tons (2015-2020)
  • Figure 19. Global Amphetamine Drug: by Route of Administration K Tons (2015-2020)
  • Figure 20. Global Amphetamine Drug: by Disease K Tons (2015-2020)
  • Figure 21. Global Amphetamine Drug: by Sales Channel K Tons (2015-2020)
  • Figure 22. Global Amphetamine Drug: by Patient K Tons (2015-2020)
  • Figure 23. South America Amphetamine Drug Share (%), by Country
  • Figure 24. Asia Pacific Amphetamine Drug Share (%), by Country
  • Figure 25. Europe Amphetamine Drug Share (%), by Country
  • Figure 26. MEA Amphetamine Drug Share (%), by Country
  • Figure 27. North America Amphetamine Drug Share (%), by Country
  • Figure 28. Global Amphetamine Drug share by Players 2020 (%)
  • Figure 29. Global Amphetamine Drug share by Players (Top 3) 2020(%)
  • Figure 30. Global Amphetamine Drug share by Players (Top 5) 2020(%)
  • Figure 31. BCG Matrix for key Companies
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 36. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 37. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 38. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 40. Mallinckrodt Company (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. Mallinckrodt Company (United Kingdom) Revenue: by Geography 2020
  • Figure 42. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 44. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 45. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2020
  • Figure 46. Purdue Pharma L.P. (United States) Revenue, Net Income and Gross profit
  • Figure 47. Purdue Pharma L.P. (United States) Revenue: by Geography 2020
  • Figure 48. Global Amphetamine Drug: by Type USD Million (2021-2026)
  • Figure 49. Global Amphetamine Drug: by Type USD Million (2021-2026)
  • Figure 50. Global Amphetamine Drug: by End Users USD Million (2021-2026)
  • Figure 51. Global Amphetamine Drug: by Route of Administration USD Million (2021-2026)
  • Figure 52. Global Amphetamine Drug: by Disease USD Million (2021-2026)
  • Figure 53. Global Amphetamine Drug: by Sales Channel USD Million (2021-2026)
  • Figure 54. Global Amphetamine Drug: by Patient USD Million (2021-2026)
  • Figure 55. South America Amphetamine Drug Share (%), by Country
  • Figure 56. Asia Pacific Amphetamine Drug Share (%), by Country
  • Figure 57. Europe Amphetamine Drug Share (%), by Country
  • Figure 58. MEA Amphetamine Drug Share (%), by Country
  • Figure 59. North America Amphetamine Drug Share (%), by Country
  • Figure 60. Global Amphetamine Drug: by Type K Tons (2021-2026)
  • Figure 61. Global Amphetamine Drug: by Type K Tons (2021-2026)
  • Figure 62. Global Amphetamine Drug: by End Users K Tons (2021-2026)
  • Figure 63. Global Amphetamine Drug: by Route of Administration K Tons (2021-2026)
  • Figure 64. Global Amphetamine Drug: by Disease K Tons (2021-2026)
  • Figure 65. Global Amphetamine Drug: by Sales Channel K Tons (2021-2026)
  • Figure 66. Global Amphetamine Drug: by Patient K Tons (2021-2026)
  • Figure 67. South America Amphetamine Drug Share (%), by Country
  • Figure 68. Asia Pacific Amphetamine Drug Share (%), by Country
  • Figure 69. Europe Amphetamine Drug Share (%), by Country
  • Figure 70. MEA Amphetamine Drug Share (%), by Country
  • Figure 71. North America Amphetamine Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Mallinckrodt Company (United Kingdom)
  • Johnson & Johnson Services, Inc. (United States)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Purdue Pharma L.P. (United States)
Select User Access Type

Key Highlights of Report


Jul 2021 247 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Amphetamine Drug Market Quantitative research analysis
Global Amphetamine Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Amphetamine Drug Market Report?

Have a Query? Click Here

Other Related Reports

Keytruda Comprehensive Study by Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others), Distribution Channel (Retail, Online), End-User (Hospitals, Clinics) Players and...
$ 3600
Neuromuscular Blocking Drugs Comprehensive Study by Distribution Channel (Online, Offline), End-User (Hospitals, Clinics, Others), Drug Class (Pachycurares, Leptocurares) Players and Region - Global ...
$ 3500
Sarcopenia Supplement Comprehensive Study by Type (Protein Supplement, Vitamin D & Calcium Supplement, Vitamin B12 Supplement), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online ph...
$ 3500
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Comprehensive Study by CRO Service (Discovery, Preclinical, Clinical Service, Laboratory Service), CMO Service (Active Ph...
$ 3750
Roll Compactor Comprehensive Study by Type (• <30Kg/Hour, • 30 – 200Kg/Hour, • >200Kg/Hour), Sales Channel (Online, Offline), End User (Pharmaceutical, Food and Beverage, Chemical, Others) Players an...
$ 3500
VLP Vaccines Comprehensive Study by Virus (Covid-19, Zika, HIV, Adeno-Associated Virus, Hepatitis C), Form (Tablet, Injectables, Capsules, Others), End Use (Hospitals, Specialty Clinics), Vaccine (Li...
$ 3650